Da Hee Han
By
Da Hee Han
Published: Oct. 13, 2017, 2:32 p.m.·
Tags:
Latent TB,
Treatment
SAN DIEGO, October 08, 2017—Discontinuation rates for the 12-dose isoniazid-rifapentine (3HP) regimen are low, and the regimen could help effectively treat latent tuberculosis infection (LTBI), confirmed a post-marketing analysis reported at IDWeek 2017.
Read More →
By
Da Hee Han
Published: Oct. 12, 2015, 3:25 p.m.·
Tags:
HIV coinfection,
Treatment
SAN DIEGO, CA—Patients with HIV and tuberculosis (TB) coinfection are discontinuing first-line antitubercular therapy (ATT) at disturbingly high rates because of side effects like skin reactions, gastrointestinal symptoms, and hepatotoxicity, according to study findings reported at IDWeek 2015.
Read More →
By
Da Hee Han
Published: Oct. 11, 2014, 7:33 p.m.·
Tags:
HIV coinfection,
Prevention
PHILADELPHIA, PA—The use of isoniazid as preventive therapy among HIV-infected patients receiving highly active antiretroviral therapy (HAART) is associated with significantly lower tuberculosis incidence, reported Bethel Shiferaw, MD, MPH, from Nassau University Medical Center, East Meadow, at IDWeek 2014.
Read More →
By
Da Hee Han
Published: Oct. 6, 2013, 9:51 p.m.·
Tags:
None
SAN FRANCISCO, CA—Pyrazinamide is safe in elderly patients >80 years old not experiencing malnourishment, low-grade ADL, and previously elevated liver enzymes, as presented by Ryutaro Tanizaki, MD, from the National Center for Global Health and Medicine, Tokyo, Japan at IDWeek 2013.
Read More →
By
Da Hee Han
Published: Oct. 6, 2013, 9:48 p.m.·
Tags:
None
SAN FRANCISCO, CA—The completion rate of a 12-dose, 3-month isoniazid/rifapentine (3HP) regimen in this study (83.7%) is comparable to its completion rate in Study 26 (82.1%), and is significantly higher than the average 55.0% completion rate for the 9-month isoniazid regimen that was reported in Arkansas for the past 5 years, according to results presented at IDWeek 2013.
Read More →
Page 1 of 1 · Total posts: 5
1